# Novavax, Inc. (NVAX) stock news and updates

As of November 5, 2026. Source: https://www.clearthesis.ai/updates/NVAX

## Our view on the Novavax, Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/NVAX

## Latest updates on Novavax, Inc.

### Third-quarter revenue and outlook beat expectations

*November 5, 2026 · earnings · significance: major · signal: positive*

Novavax reported a loss of 19 cents per share, which was better than the 35-cent loss analysts had predicted. Revenue reached 68 million dollars for the quarter, also beating expectations. The company raised its full-year revenue forecast to about 400 million dollars, a significant jump from its previous outlook. This growth is largely tied to its partnership with Sanofi, a global pharmaceutical giant. Novavax earned a 125 million dollar payment in October after Sanofi started a late-stage trial for a combined flu and COVID-19 vaccine in Europe. By letting Sanofi handle the expensive clinical trials and manufacturing, Novavax is successfully shifting to a leaner model that relies on royalties and milestone payments rather than selling vaccines itself.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1000694/000100069426000021/0001000694-26-000021-index.htm)

### Activist investor Shah Capital steps back

*November 5, 2026 · news · significance: notable · signal: positive*

Shah Capital, an investment firm that had been publicly pushing Novavax to change its strategy and board, has decided to step back from its activist role. Activist investors typically buy large stakes to pressure management into making changes they believe will raise the stock price. This move suggests that Shah Capital is satisfied with the company's recent pivot. Novavax has lately moved away from manufacturing its own vaccines and toward licensing its technology to larger partners like Sanofi. For long-term owners, this reduces the risk of public infighting and indicates that major shareholders are now aligned with the current plan.

Sources: [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-shareholder-shah-capital-step-back-activist-role-2026-10-16/)

## Novavax, Inc. earnings

In Q3 2026, reported on November 5, 2026, Novavax, Inc. posted earnings of $-0.19 per share against $-0.35 expected, and revenue of $68.3 million against $50.4 million expected.

The next earnings report is expected on November 5, 2026. Analysts expect $-0.35 per share. Revenue is expected around $50.4 million.

What to watch: Whether licensing and royalty revenue stays on track, as this recurring income is the key to proving the new business model can actually last.

## Recent analyst activity on NVAX

- October 15, 2026: Citigroup Kept rating at Sell.

## What's ahead for Novavax, Inc.

- November 5, 2026: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/NVAX
